Zimmer Biomet Holdings (NYSE:ZBH) Receives Coverage Optimism Rating of 0.16

Xavier Trudeau
Juillet 17, 2017

Norges Bank purchased a new stake in shares of Zimmer Biomet Holdings during the fourth quarter worth about $234,271,000. The analysts, on average, are forecasting a $135 price target, but the stock is already up 38.54% from its recent lows. North Star Asset Management Inc.'s holdings in Zimmer Biomet Holdings were worth $5,519,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Finally, Enterprise Financial Services Corp boosted its position in shares of Zimmer Biomet Holdings by 1.0% in the first quarter. Sandy Spring Bank now owns 1,222 shares of the medical equipment provider's stock worth $149,000 after buying an additional 20 shares during the period. Point72 Asset Management L.P. increased its position in Zimmer Biomet Holdings by 230.3% in the first quarter. Cim Investment Mangement Inc. raised its position in shares of Zimmer Biomet Holdings by 1.2% in the fourth quarter. First Manhattan Co. now owns 2,565,370 shares of the medical equipment provider's stock valued at $333,549,000 after buying an additional 305,668 shares in the last quarter.

In latest trading session, Zimmer Biomet Holdings, Inc. Finally, Acuta Capital Partners LLC bought a new position in shares of Zimmer Biomet Holdings during the fourth quarter valued at about $1,548,000.

The actual size of Jana's stake in the company is not yet clear, nor are the hedge fund's plans. Zimmer Biomet Holdings, Inc. has a 52-week low of $95.63 and a 52-week high of $133.21.

Company shares last traded at $132.49 which is a tad above $123.43, the 50 day moving average and a tad above the 200 day moving average of $117.75. The Schafer Cullen Capital Management Inc holds 973,269 shares with $119.15M value, down from 1.09M last quarter. The business had revenue of $1.98 billion during the quarter, compared to the consensus estimate of $1.96 billion. Zimmer Biomet Holdings had a return on equity of 16.80% and a net margin of 6.36%. Next quarter's EPS is estimated at $1.95 with next year's EPS projected to be $9.23. On average, equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post $8.52 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, July 28th. Stockholders of record on Friday, June 23rd will be issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.72%. The ex-dividend date is set for Wednesday the 21st of June 2017. Zimmer Biomet Holdings's dividend payout ratio (DPR) is now 39.67%. If you are viewing this story on another site, it was stolen and republished in violation of global copyright and trademark law. Levin Capital Strategies L.P. boosted its position in shares of Zimmer Biomet Holdings by 41.9% in the fourth quarter.

Several research firms have issued reports on ZBH.

Analysts await Zimmer Biomet Holdings Inc (NYSE:ZBH) to report earnings on July, 27 before the open. Sterne Agee CRT initiated the stock with "Buy" rating in Wednesday, November 4 report. On August 23 Barclays maintained a company rating of "Overweight" and moved up the price target from $140.00 to $145.00. On November 8 the company was changed to a "Neutral" in a report from Northcoast Research a cut from the previous " rating.

On December 15, 2016 the stock rating was rated "Sell" according to a UBS report which is down from the previous " rating. The company now has an average rating of "Buy" and a consensus price target of $137.19. The shares were sold at an average price of $116.47, for a total value of $10,171,441.57. Following the transaction, the insider now owns 381,886 shares in the company, valued at approximately $44,478,262.42. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Chad F. Phipps sold 6,200 shares of the stock in a transaction that occurred on Friday, May 5th. The shares were sold on May 5th for an average price of $116.98. The disclosure for this sale can be found here. Insiders have sold a total of 111,262 shares of company stock worth $13,103,927 over the last 90 days. If the stock has a value of 1, it would indicate that the price change is equivalent to that of the S&P 500 during the period.

Zimmer Biomet Holdings, Inc., launched on January 12, 2001, is involved in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

D'autres rapports CampDesrEcrues

Discuter de cet article